Friday, December 27

Tag: Biological Therapy

AstraZeneca to Buy Gracell Biotechnologies for $1.2 Billion
27Dec By adminNo Comments
World

AstraZeneca to Buy Gracell Biotechnologies for $1.2 Billion

AstraZeneca has agreed to buy Gracell Biotechnologies for a transaction value of $1.2 billion, as part of the former’s efforts to grow its cell therapies business.The upfront cash portion of the deal is $1.0 billion, a 62.0% premium to Gracell’s last closing price for its American depository shares of $6.19, AstraZeneca said in a statement Tuesday.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
AstraZeneca to Buy Gracell Biotechnologies for $1.2 Billion
26Dec By adminNo Comments
World

AstraZeneca to Buy Gracell Biotechnologies for $1.2 Billion

AstraZeneca has agreed to buy Gracell Biotechnologies for a transaction value of $1.2 billion, as part of the former’s efforts to grow its cell therapies business.The upfront cash portion of the deal is $1.0 billion, a 62.0% premium to Gracell’s last closing price for its American depository shares of $6.19, AstraZeneca said in a statement Tuesday.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Health Care Roundup: Market Talk
17Nov By adminNo Comments
World

Health Care Roundup: Market Talk

Updated Nov. 17, 2023 12:29 pm ETThe latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0846 ET – Twist Bioscience is feeling optimistic about the year ahead after orders picked up and revenue exceeded analyst expectations in its F4Q, which ended Sept. 30. The San Francisco-based biotech company is expecting momentum behind its SynBio product group to be bolstered by Express Genes, its new gene synthesis service, and for its next-generation sequencing business to grow as customers advance their development and commercial plans, CEO Emily Leproust says. Twist is guiding for annual revenue to rise 16% to 18%, with that same growth rate for its SynBio unit. Twist expects 19% to 20% revenue growth for its next-ge...
Read More